Post by Olawuyi Matthew Oluwaseun

I'm pleased to share that our research at CompChem Hub on computationally designed siRNA therapeutics targeting viruses associated with multiple sclerosis (MS) has culminated in two peer-reviewed publications. The studies focus on designing and evaluating small interfering RNA (siRNA) molecules capable of silencing viral genes from Epstein–Barr virus (EBV) and Human Herpesvirus 6A (HHV-6A), two viruses that have been implicated in the pathogenesis of multiple sclerosis. 📄 Publications 1. Hitting Epstein-Barr virus where it hurts: Computational methods exploration for siRNA therapy in alleviating Epstein-Barr virus-induced multiple sclerosis https://lnkd.in/eY7pzNxw 2. siRNA-Mediated Silencing of the HHV-6A U24 Gene in the Treatment of Human Herpes Virus 6A–Induced Multiple Sclerosis https://lnkd.in/eMFxNj4x Using computational approaches, including sequence conservation analysis, siRNA design, structural modelling, molecular docking, and molecular dynamics simulations, we identified promising siRNA candidates that warrant future experimental validation. These publications reflect my growing interest in computational pharmacology, bioinformatics, and RNA-based therapeutics and reinforce my commitment to leveraging computational tools to accelerate drug discovery. I sincerely appreciate CompChem Hub and fellow researchers for allowing me to play a part in making this possible.  Compchem looks forward to expanding this line of research through further collaborations and experimental validation. Science advances through collaboration, continuous learning, and the willingness to tackle challenging problems. I'm excited for what lies ahead. #CompchemHub #Research #ComputationalBiology #Bioinformatics #Pharmacology #DrugDiscovery #RNATherapeutics #siRNA #MultipleSclerosis #EBV #HHV6 #MolecularBiology #ComputationalPharmacology #ScientificResearch